Demopulos Gregory A Md
Demopulos Gregory A MD, CHAIR, CEO, PRES, reported a transaction classified as grant at OMEROS CORP involving 500000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 500000.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Oct 28, 2026
- Filing date
- Oct 30, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
OMER price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- grant Code A
- Identifier
- 0001437749-26-034240 Performance Stock Option (right to buy)
- Transaction date
- Oct 28, 2026 Filed Oct 30, 2026, 09:04 PM · 2d delay
- Shares
- 500,000 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 500,000 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-6 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chairman, CEO & President
- F1
No portion of the option was vested, and no shares were issued, on the grant date. The shares subject to the option will vest and become exercisable in four equal tranches subject to both (i) achievem…
0 other transactions
0 recent txs